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EXPLANATORY MEMORANDUM 
I. COUNCIL REGULATION (EEC) NO 2377/90 
On 26 June 1990, the Council adopted Regulation (EEC) No 2377/90 laying down a 
Community procedure for the establishment of maximum residue limits of veterinary 
medicinal products in foodstuffs of animal origin (OJ NoL 224, 18.8.1990, p. 1), 
hereinafter referred to as "the Regulation". The aim of this Regulation is to protect public 
health and to prevent the establishment of maximum residue limit at national level from 
hindering the free movement of veterinary medicinal products and foodstuffs within the 
European Union. 
The effect of the combined provisions of the Regulation and of Article 4 of 
Directive 81/851/EEC on the approximation of the laws of the Member States relating to 
veterinary medicinal products (OJ NoL 317, 6.11.1981, p. 1), as amended by 
Directive 90/676/EEC of 13 December 1990 (OJ No L 373, 31.12.1990, p. 15), has been 
as follows: 
since 1 January 1992, the date on which the Regulation entered into force, it has not 
been possible to authorize the placing of a veterinary medicinal product on the market 
unless a maximum residue limit has been established beforehand at Community level 
(new substance); 
substances whose use was authorized on that date have had to be progressively 
evaluated, so that from 1 January 1997 the use of substances for which maximum 
residue limits had not been established would be prohibited in the Community (old 
substances). 
Pursuant to the Regulation, on the basis of the scientific opinion of the Committee for 
Veterinary Medicinal Products (hereinafter referred to as CVMP), it falls to the 
Commission to adopt, in accordance with the procedure of the Regulatory Committee, a 
legally binding decision classifying the substance in question in one of the four annexes 
to the Regulation: 
- Annex I, restricted to substances for which a maximum residue level may be fixed 
after an evaluation of the toxicological risks that substance presents for human health; 
- Annex II contains substances not subject to maximum residue levels; 
- Annex HI covers substances for which in the absence of adequate scientific data it is 
not possible to establish a definitive maximum residue limit but which without 
presenting a hazard for the health of the consumer may be the subject of a maximum 
residue limit for a specified period required for the completion of scientific studies; 
Annex IV is for substances for which no maximum residue limit can be established 
because the substances concerned constitute, at whatever limit, a hazard to the health 
of the consumer. 
The Commission has then classified some 282 of the most widely used substances in 
veterinary medicine in one of the Annexes to the Regulation by adopting the following 
Regulations: 
Regulation (EEC) No 675/92, OJ L 73, 19.3.1992, p. 8 
Regulation (EEC) No 3093/92, OJ L 311, 28.10.1992, p. 18 
Regulation (EEC) No 895/93, OJ L 93, 17.4.1992, p. 10 
Regulation (EC) No 3425/93, OJ L 312, 15.12.1993, p. 12 
Regulation (EC) No 3426/93, OJ L 312, 15.12.1993, p. 15 
Regulation (EC) No 955/94, OJ L 108, 29.4.1994, p. 8 
Regulation (EC) No 1430/94, OJ L 156, 23.6.1994, p. 6 
Regulation (EC) No 2703/94, OJ L 287, 8.11.1994, p. 19 
Regulation (EC) No 3059/94, OJ L 323, 16.12.1994, p. 15 
Regulation (EC) No 1102/95, OJL 110, 17.5.1995, p. 9 
Regulation (EC) No 1441/95, OJ L 143, 27.6.1995, p. 22 
Regulation (EC) No 1442/95, OJ L 143, 27.6.1995, p. 26 
Regulation (EC) No 1798/95, OJ L 174, 26.7.1995, p. 20 
Regulation (EC) No 2796/95, OJ L 290, 5.12.1995, p. 1 
Regulation (EC) No 2804/95, OJ L 291, 6.12.1995, p. 8 
Regulation (EC) No 281/96, OJ L 37, 15.5.1996, p. 9 
Regulation (EC) No 282/96, OJ L 37, 15.2.1996, p. 12 
Regulation (EC) No 1140/96, OJ L 151, 26.6.1996, p. 6 
Regulation (EC) No 1147/96, OJ L 151, 26.6.1996, p. 26 
The harmonization thus achieved has enabled the Community to play a more active and 
coordinated role in the international harmonization work undertaken within the Codex 
Alimentarius Committee for residues of veterinary medicinal products in foodstuffs and 
the JECFA (Joint FAO/WHO Expert Committee on Food Additives). 
n. ADAPTATION OF COUNCIL REGULATION (EEC) No 2377/90 TO THE NEW 
COMMUNITY SYSTEM OF MARKETING AUTHORIZATIONS 
Since the Regulation was adopted, the regulatory environment for veterinary medicinal 
products has been radically altered following the entry into force of the Community 
system of marketing authorizations resulting from Council Regulation (EEC) No 2309/93 
laying down Community procedures for the authorization and supervision of medicinal 
products for human and veterinary use and establishing a European Agency for the 
Evaluation of Medicinal Products1 and Council Directives 93/40/EEC2 and 93/41/EEC.3 
The CVMP is henceforth responsible to the European Agency for the Evaluation of 
Medicinal Products (hereafter referred to as "the Agency") which deals with requests for 
authorization to place human and veterinary medicinal products on the market in 
accordance with the so-called centralized procedure and to which it falls, under 
Regulation (EEC) No 2309/93, to issue an opinion on the maximum residue limits of 
veterinary medicinal products which are acceptable in foodstuffs of animal origin. With a 
view to legal consistency, the Regulation should therefore be adapted by conferring on 
the Agency the task of dealing with applications for the establishment, amendment and 
extension of maximum residue limits and by aligning the decision making process with 
that of the centralized procedure (role of Agency Secretariat, time limits, appeals). 
Account should also be taken of Council Regulation (EC) No 297/95 on fees payable to 
the European Agency for the evaluation of medicinal products4 which lays down inter 
alia that fees are charged by the Agency for examining applications for the establishment, 
amendment and extension of maximum residue limits. 
Moreover, it is necessary to adapt the period for submitting draft measures to the 
regulatory committee to allow the Community to meet its obligations under the 
Agreements on the application of sanitary and phytosanitary measures which emerged 
from the multilateral negotiations of the Uruguay Round, approved on behalf of the 
European Community by Council Decision 94/800/EC of 22 December 1994.5 This 
agreement creates a transparency obligation as regards health measures which 
necessitates the introduction of reasonable periods for consulting members of the World 
Trade Organization. 
1
 OJ L 214, 24.8.93, p. 1. 
2
 OJL214, 24.8.93, p. 31. 
3
 OJL214, 24.8.93, p. 40. 
4
 OJ L 35, 15.2.9.95, p. 1. 
5
 OJL 336, 23.12.94. p. 1 
III. EXTENSION OF THE DEADLINE OF 1 JANUARY 1997 FOR THE REVISION 
OF OLD SUBSTANCES 
Article 7(2) of the Regulation provides for the gradual evaluation of old substances and 
Article 14 lays down that, with effect from 1 January 1997, "the administration to food 
producing animals of veterinary medicinal products containing pharmacologically active 
substances which are not mentioned in Annexes I, II or HI shall be prohibited within the 
Community". 
To this end, the Commission published as an annex to Volume VI of the Regulations on 
medicinal products in the European Community a timetable for the evaluation of old 
substances. The number of substances to be evaluated between 1992 and 1997 was then 
estimated at 400. In view of the difficulties encountered by the industry in collecting the 
data necessary to establish dossiers and by the national authorities in evaluating them, 
this timetable was changed and published in the form of a Commission communication in 
the Official Journal of the European Communities on 29 September 1993.6 
The Member States bearing most of the burden of the evaluation work through the 
CVMP were unable, however, to allocate sufficient resources for the revision work to be 
completed by the deadline originally laid down by the Council. For its part, the industry 
became involved in a major process of réévaluation and updating of dossiers. 
There is no doubt that as a result of this exercise, the market in veterinary medicinal 
products will have become more transparent, thus improving consumer protection. It is, 
however, clear that the scale of the task far exceeded available resources and that, in spite 
of the considerable efforts of the Agency since commencing its activities on 
1 January 1995, the evaluation currently underway will not be completed by 
1 January 1997. 
Therefore, in order to allow this Community procedure to continue on a sound scientific 
basis and not to deprive veterinary surgeons and other users of substances needed to 
protect animal health, the time limit originally laid down should be extended by two 
years. However, for obvious reasons of consumer protection and transparency, this 
extension should be restricted to those substances for which dossiers were presented to 
the Agency before 1 January 1996. 
OJ C 263, 29.9.93, p. 5. 
The figures below give an overview of the situation on 1 March 1996: 
Substances undergoing evaluation in 
the Agency 
Substances undergoing evaluation for 
which further data has been requested 
from the firms concerned 
Substances whose evaluation has not 
yet begun 
Total 
Annex I 
32 
22 
35 
89 
Annex II 
69 
10 
78 
157 
Total 
101 
32 
113 
246 
The evaluation of prospective Annex I substances is estimated to involve 250 hours of 
work and prospective Annex JJ substances around 30 hours of work. Therefore, 11090 
hours of work are still needed to complete the evaluation of old substances. 
Given an 8-hour working day, 1 386 working days are then still needed for this activity. 
However, the Member States do not allocate the same resources to this work. The table 
below shows the time that the national experts spend on this activity, based on a 240 
working-day year: 
France (two experts) 100% 480 days I 
Netherlands (two experts) 50% 240 days I 
United Kingdom 70% 168 days 1 
I Germany 25% 120 days Italy 25% 60 days Sweden 25% 60 days 
Denmark 25% 60 days 
I Ireland 25% 60 days 
Austria 10% 24 days 
Finland 10% 24 days 
Portugal 10% 24 days 
Spain 10% 24 days 
Belgium 10% 24 days 
Total 1368 days 
However, this calculation does not take account of the time needed for industry to 
respond to requests for additional information (around 6 months), meetings and the 
delays inherent in the decision making process. It is therefore reasonable that, to complete 
the evaluation of old substances under conditions which are satisfactory from both the 
scientific and public health protection point of view, the time limit laid down by the 
Regulation should be extended to 1 January 1999. 
IV. ESTABLISHMENT OF MAXIMUM RESIDUE LIMITS FOR SUBSTANCES 
UNDERGOING CLINICAL TRIALS 
Article 4(2) of Directive 81/851/EEC lays down that "from 1 January 1977 the Member 
States shall not permit foodstuffs for human consumption to be taken from test animals 
unless maximum residue limits have been established by the Community in accordance 
with the provisions of Regulation (EEC) No 2377/90 and an appropriate withdrawal 
period has been established to ensure that this maximum limit will not be exceeded in the 
foodstuffs". 
This means that, from 1 January 1997, unless a maximum residue limit is established 
before â clinical trial is carried out, foodstuffs from animals used in the clinical trial and 
possibly the animals themselves (regardless of the time that has elapsed since the trial) 
would have to be destroyed. 
Moreover, whereas for old substances, Article 4 of the Regulation lays down that 
provisional maximum residue limits may be established provided that there are no 
grounds for supposing that residues of the substance concerned at the level proposed 
present a hazard for the health of the consumer, it stipulates that as regards new 
substances, this possibility may be used only in "exceptional circumstances". 
Clinical trials are carried out in order to assess the effectiveness of the substance, 
relatively early in the development process and certainly well before all the information 
and data which has to be given in an application to establish a maximum residue limit for 
a pharmacologically active substance used in veterinary medicinal products in accordance 
with Annex V of Regulation (EEC) No 2377/90 is available. 
The primary objective of Regulation (EEC) No 2377/90 is to protect the health of 
consumers and it is normal that such protection should apply where animals have been 
the subject of clinical trials. However, notwithstanding this objective, it is also necessary 
to ensure that no undue damage is done to the research and development capacity of the 
pharmaceutical industry in Europe and to avoid a situation where European 
pharmaceutical companies are obliged to carry out their tests outside Europe. 
In the same way as with old substances, it is possible to establish provisional maximum 
residue limits for substances undergoing clinical trials. Annex V should be amended so 
that initially only certain data is provided, which nonetheless constitutes a sound 
scientific basis for the evaluations. To this end, a specific annex for substances 
undergoing clinical trials which are the subject of a provisional maximum residue limit 
and an appropriate withdrawal period guaranteeing protection of consumer health would 
have to be added to Regulation (EEC) 2377/90. As regards the fees to be paid to the 
Agency, a suitable solution should be applied under Regulation (EC) No 297/95,7 which 
could envisage the fee thus paid being deducible from that ultimately due in connection 
with an application made under Article 6 of the Regulation. 
OJ NoL 35, 15.2.95, p. 1. 
Proposal for a 
COUNCIL REGULATION (EC) 
amending Council Regulation (EEC) No 2377/90 laying down a 
Community procedure for the establishment of maximum residue limits 
of veterinary medicinal products in foodstuffs of animal origin 
THE COUNCIL OF THE EUROPEAN COMMUNITIES 
Having regard to the Treaty establishing the European Community, and in particular 
Article 43 thereof, 
Having regard to the proposal from the Commission, 
Having regard to the opinion of the European Parliament, 
Having regard to the opinion of the Economic and Social Committee, 
Whereas, since Council Regulation (EEC) No 2377/90 was adopted, the regulatory 
environment of veterinary medicinal products has been radically altered, in particular as a 
result of the entry into force of Council Regulation (EEC) No 2309/93 laying down 
Community procedures for the authorization and supervision of medicinal products for 
human and veterinary use and establishing a European Agency for the Evaluation of 
Medicinal Products1 and of Council Directive 93/40/EEC amending Directives 
81/851/EEC and 81/852/EEC on the approximation of the laws of the Member States 
relating to veterinary medicinal products;2 
Whereas the Committee for Veterinary Medicinal Products is henceforth responsible to 
the European Agency for the Evaluation of Medicinal Products and whereas it falls to this 
Agency, through this Committee, to issue an opinion on the maximum residue limits of 
veterinary medicinal products which are acceptable in foodstuffs of animal origin in 
accordance with Regulation (EEC) No 2377/90; 
Whereas Council Regulation (EC) No 297/95 of 10 February 1995 on fees payable to the 
European Agency for the Evaluation of Medicinal Products3 establishes the fees payable 
to the Agency for examining applications for the establishment, amendment and 
extension of maximum residue limits; 
Whereas it is necessary, consequently, to adapt Regulation (EEC) 2377/90 by conferring 
on the Agency the task of dealing with applications for the establishment, amendment 
and extension of maximum residue limits and by aligning the decision-making process 
with respect to the authorization and supervision of medicinal products for veterinary use 
with that introduced by Regulation (EEC) No 2309/93; 
Whereas the Agreement on the application of sanitary and phytosanitary measures which 
emerged from the multilateral negotiations of the Uruguay Round, approved on behalf of 
the European Community by Council Decision 94/800/EC of 22 December 1994 
concerning the conclusion on behalf of the European Community, as regards matters 
within its competence, of the agreements reached in the Uruguay Round multilateral 
1
 OJ No L 214, 24.8.1993, p. 1. 
2
 OJ No L 214, 24.8.1993, p. 31. 
3
 OJ No L 35, 15.2.1995, p. 1. 
negotiations (1986-1994)4, creates transparency obligations as regards health measures; 
whereas Regulation (EEC) No 2377/90 must therefore be adapted in order to enable the 
Community to fulfil its obligations under this Agreement; 
Whereas Council Directive 81/851/EEC as amended by Directive 93/40/EEC prohibits 
from 1st January 1997 foodstuffs for human consumption being taken from animals used 
for clinical trials unless" maximum residue limits have been established by the 
Community; Whereas, Regulation (EEC) No 2377/90 has to be amended in order to 
allow the use of this procedure for substances undergoing clinical trials; for this purpose, 
the level of development of the substance concerned should be taken into account; the 
information and particulars to be included in an application for the establishment of a 
MRL within the meaning of Annex V of this Regulation should be reviewed; 
Whereas it is necessary to maintain on the market substances the use of which was 
authorized on the date when Regulation (EEC) No 2377/90 entered into force and for 
which applications were submitted to the Commission or to the Agency before 
1 January 1996, in order to make it possible to continue their scientific evaluation in the 
best possible conditions, given the resources available, 
HAS ADOPTED THIS REGULATION 
Article 1 
Regulation (EC) 2377/90 is amended as follows: 
1. The following Article is inserted: 
"Article 4(a) 
A provisional maximum residue limit may be established for a pharmacologically 
active substance undergoing clinical trials, provided that there are no grounds for 
supposing that residues of the substance concerned at the level proposed present a 
health hazard to consumers. A suitable waiting period shall be fixed to guarantee that 
this provisional maximum residue limit is respected. This provisional maximum 
residue limit shall apply for a defined period of time, which shall not exceed two 
years. 
The list of pharmacologically active substances used in the context of clinical trials for 
which provisional maximum residue limits have been established, together with their 
appropriate time periods, shall be contained in Annex 111(a), which shall be adopted in 
accordance with the procedure laid down in Article 8. Except as provided for in 
Article 9, any amendments to Annex IH(a) shall be adopted in accordance with the 
same procedure." 
4
 O.J. N° L 336 of 23.12.94, p. 1 
2. Article 6 is replaced by the following text: 
"Article 6 
1. In order to obtain the inclusion in Annex I, II or HI of a pharmacologically active 
substance which is intended for use in veterinary medicinal products for 
administration to food- producing animals, an application to establish a maximum 
residue limit shall be submitted to the European Agency for the Evaluation of 
Medicinal Products set up by Council Regulation (EEC) No 2309/93, hereinafter 
referred to as the "Agency". 
This application shall contain the information and particulars referred to in Annex 
V and shall conform with the principles laid down in Directive 81/852/EEC. When 
a provisional maximum residue limit as referred to in Article 4(a) of this Regulation 
has been established, only the data needed to complete Annex V have to be 
supplied. 
2. In order to obtain the inclusion in Annex 111(a) of a pharmacologically active 
substance administered to food-producing animals and used in the context of 
clinical trials, an application to establish a provisional maximum residue limit shall 
be submitted to the Agency. This application shall contain the information and 
particulars referred to in Annex V, which shall be amended to that end. 
3. The application shall also be accompanied by the fee due to the Agency for 
examining the application fixed by Regulation (EC) No 297/95. 
3. Article 7 is replaced by the following text: 
"Article 7 
1. The Committee for Veterinary Medicinal Products referred to in Article 27 of 
Regulation (EEC) No 2309/93, hereinafter referred to as the "Committee", shall be 
responsible for formulating the Agency's opinion on the classification of substances 
in Annexes I, H, HI, 111(a) or IV of this Regulation. 
2. Articles 52 and 53 of Regulation (EEC) No 2309/93 are applicable mutatis 
mutandis for the purposes of this Regulation. 
3. The Agency shall ensure that the Committee's opinion is delivered within a period 
of 120 days following the reception of a valid application. If the information 
submitted by the applicant is not sufficient to enable such an opinion to be 
prepared, the Committee may ask the applicant to supply additional information 
within a specific time limit. The deadline for the opinion shall then be deferred 
until the additional information has been received. 
4. The Agency shall forward the opinion to the applicant. Within 15 days of receipt of 
the opinion, the applicant may provide written notice to the Agency that he wishes 
to appeal. In that case he shall forward the detailed grounds for his appeal to the 
Agency within 60 days of receipt of the opinion. Within 60 days of the receipt of 
the grounds for appeal, the Committee shall consider whether its opinion should be 
revised and the reasons for the conclusion reached on the appeal shall be annexed 
to the report referred to in paragraph 7. 
11 
5. The Agency shall forward the definitive opinion of the Committee within 30 days 
of its adoption both to the Commission and to the applicant. The opinion shall be 
accompanied by a report describing the safety evaluation of the substance by the 
Committee and which shall give the grounds for its conclusions. 
6. The Commission shall prepare draft measures taking account of Community 
legislation and shall start the procedure provided for in Article 8. The Committee 
referred to in Article 8 shall adapt its rules of procedure in order to take account of 
the tasks conferred upon it by this Regulation. 
4. In Article 8, paragraph 1 is replaced by the following text: 
"1. Where the procedure laid down in this Article is to be followed, the Commission 
shall be assisted by the Standing Committee for Veterinary Medicinal Products." 
5. In Article 10, paragraph 1 is replaced by the following text: 
" 1. Where the procedure laid down in this Article is to be followed, the Commission 
shall be assisted by the Standing Committee for Veterinary Medicinal Products." 
6. Article 12 is replaced by the following text: 
"Article 12 
As soon as possible after the amendment of Annexes I, H, IQ, Ilia or IV, the Agency 
shall publish a summary of the assessment of the safety of the substances concerned 
that have been examined by the Committee. The Agency shall provide the competent 
authorities with appropriate methods of analysis for tracing residues. The confidential 
nature of any proprietary data shall be respected. " 
7. In Article 13, the terms "in Annex I or III" are replaced by "in Annex I, EQ or nia". 
8. Article 14 is replaced by the following text: 
"Article 14 
With effect from 1 January 1997, the administration to food-producing animals of 
veterinary medicinal products containing pharmacologically active substances which 
are not mentioned in Annexes I, II or III shall be prohibited within the Community. 
With regard to substances whose use was authorized in veterinary medicinal products 
before the date on which this Regulation entered into force and for which applications 
to establish maximum residue limits were submitted either to the Commission.or to 
the Agency before 1 January 1996, the prohibition date indicated in the previous 
subparagraph shall be deferred to 1 January 1999. Within three months of the adoption 
of this Regulation, the Agency will publish a list of these substances. 
As from 1 January 1997, the Member States shall not allow foodstuffs destined fnr 
human consumption to originate from animals that have been subjected to clinical 
trails unless the substance in question is mentioned in Annex Ilia." 
12 
Article 2 
This Regulation shall enter into force on 1 January 1997. 
This Regulation shall be binding in its entirety and directly applicable in all 
Member States. 
Done at 
For the Council 
The President 
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